Inhibition of JAK3 Reduces Arthritis Symptoms in Rodent Models
Author Information
Author(s): Milici Anthony J, Kudlacz Elizabeth M, Audoly Laurent, Zwillich Samuel, Changelian Paul
Primary Institution: Pfizer Global Research and Development
Hypothesis
The study aims to evaluate the efficacy of CP-690550, a JAK3 inhibitor, in reducing symptoms of rheumatoid arthritis in rodent models.
Conclusion
CP-690550 effectively reduced clinical and histological signs of rheumatoid arthritis in both murine and rat models.
Supporting Evidence
- CP-690550 reduced clinical scores in both murine and rat models of arthritis.
- A dose-dependent response was observed, with higher doses leading to greater reductions in disease symptoms.
- Histological evaluations showed significant reductions in joint damage with CP-690550 treatment.
Takeaway
A new medicine called CP-690550 helps make sick joints feel better in mice and rats with arthritis.
Methodology
The study used murine collagen-induced and rat adjuvant-induced arthritis models, administering CP-690550 via osmotic mini-pumps and assessing arthritis through clinical scores and histological evaluations.
Potential Biases
Potential bias due to the involvement of authors from Pfizer, the manufacturer of CP-690550.
Limitations
The study was conducted in rodent models, which may not fully replicate human rheumatoid arthritis.
Participant Demographics
Male DBA/J1 mice and male Lewis rats were used in the study.
Statistical Information
P-Value
p<0.0001
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website